AstraZeneca recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting significant advancements in treatment for high-risk non-muscle-invasive bladder cancer.

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug prices sent shares of pharmaceuticals companies lower across the ...

Earlier this year, AstraZeneca took Imfinzi to new heights in muscle-invasive bladder cancer (MIBC) with an FDA nod that made it the first immunotherapy cleared to treat patients both before and ...

On Thursday, May 8, 2025, a three-judge panel of the Third Circuit affirmed the district court’s rejection of AstraZeneca’s constitutional and regulatory challenge to the Negotiation Program.

May 8 (Reuters) - A federal appeals court on Thursday shut down AstraZeneca’s challenge to the U.S. government’s program that gives the Medicare health insurance plan the power to negotiate ...

As health systems across the Middle East and Africa confront the dual pressures of rising non-communicable diseases (NCDs) and persistent access gaps, AstraZeneca is placing health equity at the ...

ABU DHABI: The Abu Dhabi Public Health Centre (ADPHC) and AstraZeneca FZ LLC (AstraZeneca) have signed a Memorandum of Understanding (MoU) to launch a collaborative public health project to strengthen ...

AstraZeneca has a better P/E ratio of 27.25 than the aggregate P/E ratio of 27.19 of the Pharmaceuticals industry. Ideally, one might believe that AstraZeneca Inc. might perform better in the ...

Drugmakers said it could cost them $1 trillion over the next decade. A U.S. appeals court shut down AstraZeneca’s challenge to the U.S. government program that gives Medicare the power to ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

The AstraZeneca (LSE: AZN) share price slumped 5% when the market opened on Monday (12 May). Fellow UK pharma giant GSK dipped too, losing 3.5% in early trading. Both regained a bit, with AstraZeneca ...